The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
MK-6837 has been discontinued, the company discloses.
The two companies have been involved in recent licensing deals.
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Dispatch Bio’s virus therapy DV-10 enters phase 1.
